|

Selumetinib Sulfate Clinical Trials

2 actively recruiting trials across 1 location

Also known as: AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate

Pipeline

Phase 2: 2

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Recurrent Ovarian Carcinoma2
  • Recurrent Primary Peritoneal Carcinoma2
  • Recurrent Fallopian Tube Carcinoma2
  • Recurrent Endometrial Carcinoma2
  • Cancer2

Birmingham, Alabama2 trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.